Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials

July 6th 2017

The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab (Keytruda) trials and ordered the discontinuation of the lenalidomide/dexamethasone/pembrolizumab arm of the KEYNOTE-023 trial in patients with multiple myeloma.

Dr. Kumar Discusses Ixazomib in Multiple Myeloma

July 5th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.

Dr. Kumar Discusses Advances in the Field of Multiple Myeloma

June 29th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.

Comparison of Induction Therapies Prior to ASCT Favors Novel Quadruple Over Triplet Regimens

June 24th 2017

Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.

Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma

June 24th 2017

Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.

Response Rate Hits 100% for bb2121 in Multiple Myeloma

June 23rd 2017

All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.

Future Directions in Multiple Myeloma

June 21st 2017

Emerging Agents for Multiple Myeloma

June 21st 2017

CAR T-Cell Therapy for Multiple Myeloma

June 21st 2017

Immunotherapy for Multiple Myeloma

June 21st 2017

Sequencing Therapies in Multiple Myeloma

June 21st 2017

Continuing IMiD Therapy after Myeloma Relapse

June 21st 2017

Antibodies for Relapsed/ Refractory Multiple Myeloma

June 21st 2017

Maintenance Therapy for Multiple Myeloma

June 21st 2017

Optimal Timing for Transplantation in Myeloma

June 21st 2017

Risk Stratification for Myeloma

June 21st 2017

MRD Negativity in Multiple Myeloma

June 21st 2017

Goals of Therapy for Symptomatic Myeloma

June 21st 2017

Dr. Usmani Discusses CAR T-Cell Therapy in Multiple Myeloma

June 19th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses CAR T-cell therapy in multiple myeloma.

FDA Accepts Denosumab sBLA for Multiple Myeloma

June 19th 2017

The FDA has accepted a supplemental biologics license application for the use of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.